PROFILES - Connect with RTRN Researchers

Adebayo Oyekan
Title Dr.
Faculty Rank Associate Professor
Degree D.V.M., Ph.D.
Institution Texas Southern University
Department Department of Pharmaceutical Science
Clusters Infectious and Immunological Diseases
Texas Southern University
3100 Cleburne Street
City Houston
State TX
Postal Code 77004
Telephone 713-313-4341
Fax 713-313-4342
QR Barcode

Narrative icon

Not Available

Publications icon

  Check NIH Public Access Policy Compliance

Please wait
1. Ozurumba E, Mathew O, Ranganna K, Choi M, Oyekan A. Regulation of hypoxia inducible factor/prolyl hydroxylase binding domain proteins 1 by PPARa and high salt diet. J Basic Clin Physiol Pharmacol. 2018 Mar 28; 29(2):165-173.
2. Alshaman R, Truong L, Oyekan A. Role of mechanistic target of rapamycin (mTOR) in renal function and ischaemia-reperfusion induced kidney injury. Clin Exp Pharmacol Physiol. 2016 Nov; 43(11):1087-1096.
3. Qasim SA, Oyekan A, Boyd RP, Kieffer WK, Panose P. Consenting patients with femoral neck fractures--how well are we involving the patient's relatives? J Perioper Pract. 2016 Jun; 26(6):148-52.
4. Igbe I, Omogbai EK, Oyekan AO. Renal effects of glucose transporter 4 in N?-nitro-L-arginine/ /high salt-induced hypertensive rats. Bratisl Lek Listy. 2015; 116(1):57-63.
5. Dallatu MK, Nwokocha E, Agu N, Myung C, Newaz MA, Garcia G, Truong LD, Oyekan AO. The Role of Hypoxia-Inducible Factor/Prolyl Hydroxylation Pathway in Deoxycorticosterone Acetate/Salt Hypertension in the Rat. J Hypertens (Los Angel). 2014 Dec; 3(6).
6. Dallatu MK, Choi M, Oyekan AO. Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal. J Hypertens. 2013 Oct; 31(10):2043-9.
7. Rizvi YQ, Mehta CS, Oyekan A. Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis. Vascul Pharmacol. 2013 Nov-Dec; 59(5-6):144-51.
8. Igbe I, Omogbai EK, Oyekan AO. Role of GLUT4 on angiotensin 2-induced systemic and renal hemodynamics. J Exp Pharmacol. 2013; 5:1-13.
9. Adedapo AA, Oyekan AO. Effects of fenofibrate, a PPAR-a ligand, on the haemodynamics of glycerol-induced renal failure in rats. Hum Exp Toxicol. 2013 Mar; 32(3):323-31.
10. Yakubu MA, Sofola OA, Igbo I, Oyekan AO. Impaired endothelium-dependent and -independent relaxation of aorta from diabetic rats. Bratisl Lek Listy. 2012; 113(2):59-63.
11. Oyekan A. PPARs and their effects on the cardiovascular system. Clin Exp Hypertens. 2011; 33(5):287-93.
12. Fidelis P, Wilson L, Thomas K, Villalobos M, Oyekan AO. Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med (Maywood). 2010 Nov; 235(11):1365-74.
13. Yousefipour Z, Oyekan A, Newaz M. Interaction of oxidative stress, nitric oxide and peroxisome proliferator activated receptor gamma in acute renal failure. Pharmacol Ther. 2010 Mar; 125(3):436-45.
14. Newaz M, Yousefipour Z, Oyekan A. Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure. Ren Fail. 2010 Jan; 32(3):384-90.
15. Yakubu MA, Nsaif RH, Oyekan AO. Regulation of cerebrovascular endothelial peroxisome proliferator activator receptor alpha expression and nitric oxide production by clofibrate. Bratisl Lek Listy. 2010; 111(5):258-64.
16. Newaz M, Ranganna K, Truong LD, Oyekan A. Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypertens. 2009 Nov; 27(11):2223-31.
17. Yousefipour Z, Oyekan A, Newaz M. Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am J Nephrol. 2009; 30(3):201-8.
18. Banks T, Oyekan A. Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypertens. 2008 Mar; 26(3):468-77.
19. Obih P, Oyekan AO. Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice. Blood Press. 2008; 17(1):55-63.
20. Anozie O, Ross R, Oyekan AO, Yakubu MA. Differential modulation of bradykinin-induced relaxation of endothelin-1 and phenylephrine contractions of rat aorta by antioxidants. Acta Pharmacol Sin. 2007 Oct; 28(10):1566-72.
21. Yousefipour Z, Hercule H, Truong L, Oyekan A, Newaz M. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure. J Pharmacol Exp Ther. 2007 Aug; 322(2):461-8.
22. Yousefipour Z, Hercule H, Oyekan AO, Newaz MA. Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPARgamma gene. Ren Fail. 2007; 29(7):903-10.
23. Yakubu MA, Nsaif RH, Oyekan AO. peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture. J Pharmacol Exp Ther. 2007 Feb; 320(2):774-81.
24. Blanton A, Nsaif R, Hercule H, Oyekan A. Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypertens. 2006 Sep; 24(9):1865-72.
25. Newaz MA, Yousefipour Z, Oyekan A. Oxidative stress-associated vascular aging is xanthine oxidase-dependent but not NAD(P)H oxidase-dependent. J Cardiovasc Pharmacol. 2006 Sep; 48(3):88-94.
26. Williams J, Bogwu J, Oyekan A. The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice. J Hypertens. 2006 Jul; 24(7):1429-36.
27. Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res. 2006 Sep; 54(3):234-40.
28. Long DA, Newaz MA, Prabhakar SS, Price KL, Truong LD, Feng L, Mu W, Oyekan AO, Johnson RJ. Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. Kidney Int. 2005 Nov; 68(5):2154-63.
29. Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res. 2005 Nov 11; 579(1-2):163-71.
30. Oyekan AO. Differential effects of 20-hydroxyeicosatetraenoic acid on intrarenal blood flow in the rat. J Pharmacol Exp Ther. 2005 Jun; 313(3):1289-95.
31. Yakubu MA, Sofola OA, Igbo I, Oyekan AO. Link between free radicals and protein kinase C in glucose-induced alteration of vascular dilation. Life Sci. 2004 Oct 29; 75(24):2921-32.
32. Ajayi AA, Ogungbade GO, Hercule HC, Oyekan AO, Mutembei L. Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA(2) mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats. Diabetes Res Clin Pract. 2004 Mar; 63(3):155-69.
33. Newaz MA, Ranganna K, Oyekan AO. Relationship between PPARalpha activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacol. 2004 Feb 06; 4:1.
34. Ajayi AA, Newaz M, Hercule H, Saleh M, Bode CO, Oyekan AO. Endothelin-like action of Pausinystalia yohimbe aqueous extract on vascular and renal regional hemodynamics in Sprague Dawley rats. Methods Find Exp Clin Pharmacol. 2003 Dec; 25(10):817-22.
35. Sacerdoti D, Abraham NG, Oyekan AO, Yang L, Gatta A, McGiff JC. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther. 2004 Feb; 308(2):636-43.
36. Sofola O, Yakubu M, Igbo I, Newaz M, Oyekan A. High salt diet modulates cAMP- and nitric oxide-mediated relaxation responses to isoproterenol in the rat aorta. Eur J Pharmacol. 2003 Aug 08; 474(2-3):241-7.
37. Newaz MA, Yousefipour Z, Hercule H, Truong L, Oyekan A. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection. Clin Exp Hypertens. 2003 Aug; 25(6):335-47.
38. Udosen IT, Jiang H, Hercule HC, Oyekan AO. Nitric oxide-epoxygenase interactions and arachidonate-induced dilation of rat renal microvessels. Am J Physiol Heart Circ Physiol. 2003 Nov; 285(5):H2054-63.
39. Ogungbade GO, Akinsanmi LA, Jiang H, Oyekan AO. Role of epoxyeicosatrienoic acids in renal functional response to inhibition of NO production in the rat. Am J Physiol Renal Physiol. 2003 Nov; 285(5):F955-64.
40. Hercule HC, Wang MH, Oyekan AO. Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat. J Physiol. 2003 Sep 15; 551(Pt 3):971-9.
41. Oyekan AO. Contributions of nitric oxide and prostanoids and their signaling pathways to the renal medullary vasodilator effect of U46619 (9-11-dideoxy-11 alpha,9a-epoxymethano-prostaglandin F(2a)) in the rat. J Pharmacol Exp Ther. 2003 Feb; 304(2):507-12.
42. Carroll MA, Ferreri NR, Escalante BA, Oyekan AO, McGiff JC. Cytochrome P450 arachidonic acid metabolites modulate renal tubular function. Adv Exp Med Biol. 2003; 525:67-9.
43. Ajayi AA, Hercule H, Cory J, Hayes BE, Oyekan AO. Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diabetes Res Clin Pract. 2003 Jan; 59(1):11-24.
44. Oyekan A. Nitric oxide inhibits renal cytochrome P450-dependent epoxygenases in the rat. Clin Exp Pharmacol Physiol. 2002 Nov; 29(11):990-5.
45. Hercule H, Oyekan A. Renal cytochrome p450 oxygenases and preglomerular vascular response to arachidonic acid and endothelin-1 following ischemia/reperfusion. J Pharmacol Exp Ther. 2002 Aug; 302(2):717-24.
46. Newaz MA, Oyekan AO. Contribution of renal oxygenases to glycerol-induced acute renal failure in the rat. J Cardiovasc Pharmacol. 2002 Jun; 39(6):834-41.
47. Newaz MA, Yousefipour Z, Oyekan A. Effects of pergolide on blood pressure and tissue injury in DOCA-salt hypertension. Blood Press. 2002; 11(2):110-5.
48. Escalante BA, McGiff JC, Oyekan AO. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol Renal Physiol. 2002 Jan; 282(1):F144-50.
49. Morgan ET, Ullrich V, Daiber A, Schmidt P, Takaya N, Shoun H, McGiff JC, Oyekan A, Hanke CJ, Campbell WB, Park CS, Kang JS, Yi HG, Cha YN, Mansuy D, Boucher JL. Cytochromes P450 and flavin monooxygenases--targets and sources of nitric oxide. Drug Metab Dispos. 2001 Nov; 29(11):1366-76.
50. Newaz MA, Oyekan AO. Vascular responses to endothelin-1, angiotensin-II, and U46619 in glycerol-induced acute renal failure. J Cardiovasc Pharmacol. 2001 Oct; 38(4):569-77.
51. Bautista R, Sánchez A, Hernández J, Oyekan A, Escalante B. Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension. 2001 Sep; 38(3 Pt 2):669-73.
52. Interactions of the renin-angiotensin system and alpha-1 adrenoceptors on renal hemodynamics in healthy and acute renal failure rats: the role of nitric oxide. Blood Press. 2001; 10(4):238-46.
53. Hercule HC, Oyekan AO. Role of NO and cytochrome P-450-derived eicosanoids in ET-1-induced changes in intrarenal hemodynamics in rats. Am J Physiol Regul Integr Comp Physiol. 2000 Dec; 279(6):R2132-41.
54. Oyekan AO. Cytochrome p450-dependent metabolites of arachidonic acid and renal function in the rat. Clin Exp Pharmacol Physiol. 2000 Aug; 27(8):581-6.
55. Hercule HC, Oyekan AO. Cytochrome P450 omega/omega-1 hydroxylase-derived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther. 2000 Mar; 292(3):1153-60.
56. Oyekan AO, Youseff T, Fulton D, Quilley J, McGiff JC. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest. 1999 Oct; 104(8):1131-7.
57. Oyekan AO, McAward K, Conetta J, Rosenfeld L, McGiff JC. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol. 1999 Mar; 276(3 Pt 2):R766-75.
58. Oyekan AO, McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome p450-derived arachidonate metabolites. Br J Pharmacol. 1998 Nov; 125(5):1065-73.
59. Oyekan AO, McGiff JC. Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am J Physiol. 1998 Jan; 274(1 Pt 2):R52-61.
60. Oyekan AO, McAward K, McGiff JC. Renal functional effects of endothelins: dependency on cytochrome P450-derived arachidonate metabolites. Biol Res. 1998; 31(3):209-15.
61. Oyekan A, Balazy M, McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II. Am J Physiol. 1997 Jul; 273(1 Pt 2):R293-300.
62. Oyekan AO. Cryptolepine-induced vasodilation in the isolated perfused kidney of the rat: role of G-proteins, K+ and Ca2+ channels. Eur J Pharmacol. 1995 Oct 04; 285(1):1-9.
63. Oyekan AO. The suppression by lipopolysaccharide of cytochrome P450-dependent renal vasodilation in the rat is mediated by nitric oxide. Eur J Pharmacol. 1995 Apr 24; 277(2-3):123-32.
64. Oyekan AO. Role of the cytochrome P450 enzyme system as a humoral modulator of vasomotor responses in rat renal vasculature. J Cardiovasc Pharmacol. 1994 Aug; 24(2):238-46.
65. Oyekan AO. Role of the endothelium and cyclic GMP in renal vasodilator responses to cryptolepine in rats. J Cardiovasc Pharmacol. 1994 Apr; 23(4):602-11.
66. Oyekan AO, McGiff JC, Rosencrantz-Weiss P, Quilley J. Relaxant responses of rabbit aorta: influence of cytochrome P450 inhibitors. J Pharmacol Exp Ther. 1994 Jan; 268(1):262-9.
67. Oyekan AO, Ablordeppey SY. Effects of cryptolepine on collagen-induced aggregation and on the mobilization and metabolism of arachidonic acid by rabbit platelets. Gen Pharmacol. 1993 Sep; 24(5):1285-90.
68. Oyekan AO, Ablordeppey SY. The mechanism(s) of the antiaggregatory effects of cryptolepine: the role of cyclic adenosine monophosphate and cellular Ca2+. Gen Pharmacol. 1993 Mar; 24(2):461-9.
69. Isitor GN, Njoku CO, Adogwa AO, Oyekan AO. Study of efficacy of Lamstreptocide A & B on cases of dermatophilosis within the Caribbean. Rev Elev Med Vet Pays Trop. 1993; 46(1-2):303-8.
70. Oyekan AO, Botting JH. Relationship between gender difference in intravascular aggregation of platelets and the fibrinolytic pathway in the rat. Arch Int Pharmacodyn Ther. 1991 Sep-Oct; 313:176-92.
71. Oyekan AO, McGiff JC, Quilley J. Cytochrome P-450-dependent vasodilation of rat kidney by arachidonic acid. Am J Physiol. 1991 Sep; 261(3 Pt 2):H714-9.
72. Oyekan AO, Botting JH. Adrenaline inhibits adenosine diphosphate induced intravascular aggregation of rat platelets through stimulation of alpha 2 adrenoceptors. Cardiovasc Res. 1991 May; 25(5):431-7.
73. Oyekan AO, McGiff JC, Quilley J. Cytochrome P-450-dependent vasodilator responses to arachidonic acid in the isolated, perfused kidney of the rat. Circ Res. 1991 Apr; 68(4):958-65.
74. Oyekan AO, Onabanjo AO. Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice. Haemostasis. 1991; 21(6):360-9.
75. Oyekan AO, Botting JH. Pharmacodynamic interaction between oestradiol and adrenaline on intravascular aggregation induced by adenosine diphosphate in the rat. Arch Int Pharmacodyn Ther. 1990 Jul-Aug; 306:148-60.
76. Botting JH, Oyekan AO, Hammady F. Inhibition of intravascular platelet aggregation in the rat by adrenaline. Pol J Pharmacol Pharm. 1990 May-Jun; 42(3):291-9.
77. Oyekan AO, Botting JH. Indium-111 oxine technique of studying platelet aggregation in vivo. Some physiological considerations. Acta Haematol. 1990; 83(2):57-64.
78. Oyekan AO, Okafor JP. Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. J Ethnopharmacol. 1989 Nov; 27(1-2):141-8.
79. Oyekan AO, Botting JH. The influence of adrenaline on gender difference in adenosine diphosphate-induced aggregation of platelets in the rat. Thromb Haemost. 1988 Dec 22; 60(3):481-5.
80. Oyekan AO. There is no evidence of sexual dimorphism in platelet reactivity in the rat. Pharmacology. 1988; 37(4):232-9.
81. Oyekan AO, Botting JH, Noamesi BK. Cryptolepine inhibits platelet aggregation in vitro and in vivo and stimulates fibrinolysis ex vivo. Gen Pharmacol. 1988; 19(2):233-7.
82. Beijer L, Botting J, Crook P, Oyekan AO, Page CP, Rylander R. The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig. Br J Pharmacol. 1987 Dec; 92(4):803-8.
83. Oyekan AO, Botting JH. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1. Prostaglandins. 1987 Sep; 34(3):359-66.
84. Oyekan AO, Botting JH. A minimally invasive technique for the study of intravascular platelet aggregation in anesthetized rats. J Pharmacol Methods. 1986 Jun; 15(3):271-7.
85. Oyekan AO, Laniyonu AA. Interaction by bendrofluazide with acetylsalicylic acid. Gen Pharmacol. 1986; 17(2):251-4.
86. Oyekan AO, Thomas WO. The energetics of the interaction of piroxicam with plasma albumin. J Pharm Pharmacol. 1984 Dec; 36(12):831-4.
87. Oyekan AO, Laniyonu AA. Studies on the contributive effects of the different constituents of cow's urine concoction in rats (Part I). Trop Geogr Med. 1984 Jun; 36(2):193-9.
88. Oyekan AO, Laniyonu AA. Studies on the contributive effects of the different constituents of cow's urine concoction in rats (Part II). Trop Geogr Med. 1984 Jun; 36(2):201-6.
89. Oyekan AO, Laniyonu AA, Ashorobi RB. Interaction between frusemide and aspirin. Gen Pharmacol. 1984; 15(2):163-6.

Research Resources icon

Funding Opportunities icon

Browse active NIH & NSF funding opportunities, requests for applications (RFAs), and program announcements (PAs)

Publications Timeline

Top MeSH Keywords

Tree Map of Keyword Semantic Groups (Categories)

Left-click a node to move down the tree, right-click the graph to move back up the tree

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
Last Name
Nitric Oxide
Cytochrome P-450 Enzyme System
See all (404) keywords
See all (5) people See all (38) people

RTRN Collaboration and Professional Networking Feedback